title: Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine.
abstract: The influence of concomitant administration of an antiemetic agent on the course of nausea was assessed in a field trial of intramuscular dihydroergotamine for the treatment of acute migraine. Of 311 migraine patients enrolled onto the study, 62% (191 of 311) experienced nausea at the outset; 38% (119 of 311) did not. Of those with nausea at the outset, 54% (103 of 191) received an antiemetic. Of those without nausea at the outset, 25% (30 of 119) received an antiemetic. Thus, a total of 43% (133 of 311) of patients received a concomitant antiemetic, whereas 57% (177 of 311) received dihydroergotamine alone. When changes in the incidence of nausea were compared at 30 and 60 minutes after dihydroergotamine, an antiemetic effect was discerned in patients treated with or without a concomitant antiemetic. Antiemetic treatment yielded no significant difference in the percentage of patients experiencing nausea during the study. At baseline, 50% (88 of 177) of patients who received dihydroergotamine alone experienced nausea compared with 77% (103 of 133) of those who received an antiemetic. At the 30-minute point, 35% (61 of 173) of patients who received dihydroergotamine alone still experienced nausea versus 47% (62 of 133) of patients who received an antiemetic. At the 60-minute point, only 24% (42 of 174) of those given dihydroergotamine alone had nausea, compared with 38% (50 of 132) given concomitant antiemetic. Ongoing nausea seems to be a manifestation of the migraine process rather than an adverse effect associated with intramuscular dihydroergotamine.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Palm Beach Headache Center, FL 33407.
authors.forename: P
authors.initials: P
authors.lastname: Winner
authors.forename: D
authors.initials: D
authors.lastname: Dalessio
authors.forename: N
authors.initials: N
authors.lastname: Mathew
authors.forename: C
authors.initials: C
authors.lastname: Sadowsky
authors.forename: L J
authors.initials: LJ
authors.lastname: Turkewitz
authors.forename: F
authors.initials: F
authors.lastname: Sheftell
authors.forename: S D
authors.initials: SD
authors.lastname: Silberstein
authors.forename: S
authors.initials: S
authors.lastname: Solomon
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D002648:Child; D004087:Dihydroergotamine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015994:Incidence; D007273:Injections, Intramuscular; D008297:Male; D008881:Migraine Disorders / Q000150:complications* / Q000188:drug therapy*; D009325:Nausea / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*; D009819:Office Visits; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D000932:Antiemetics; D004087:Dihydroergotamine